Imaxio, a biopharmaceutical company specializing in vaccines, announced it has signed a license option agreement with a major animal health laboratory. The aim of the agreement is to develop a number of veterinary vaccines using Imaxio's IMX313 technology. IMX313 is designed to enhance the immune response and the effectiveness of vaccines with which it is combined.
The agreement grants the partner permission to carry out its own evaluation of Imaxio's IMX313 technology. Depending on the results of the evaluation, the agreement allows the option of a license agreement to use IMX313 in developing vaccines for a total of four animal health indications. The name of the partner and the technical and financial terms of the agreement are not disclosed.
"This new agreement with a major player in veterinary pharmacy is a further boost to our confidence in the IMX313 technology, following Imaxio signing the license option with Merial last December. The IMX313 technology is crucial to our continued in-house development of vaccines for tuberculosis, flu, Staphylococcus aureus and veterinary cryptosporidiosis," said Alexandre Le Vert, CEO of Imaxio.